A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY‐PD III)

OBJECTIVE: To describe the rationale for a novel study design and baseline characteristics of a disease‐modifying trial of isradipine 10 mg daily in early Parkinson disease (PD). METHODS: STEADY‐PDIII is a 36‐month, Phase 3, parallel group, placebo‐controlled study of the efficacy of isradipine 10 m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Clin Transl Neurol
Main Authors: Biglan, Kevin M., Oakes, David, Lang, Anthony E., Hauser, Robert A., Hodgeman, Karen, Greco, Brittany, Lowell, Jillian, Rockhill, Rebecca, Shoulson, Ira, Venuto, Charles, Young, Diony, Simuni, Tanya
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5454402/
https://ncbi.nlm.nih.gov/pubmed/28589163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.412
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados